Acute Myeloid Leukemia Market To Reach USD 5.1 Billion By 2032
06 déc. 2023 06h30 HE
|
DataHorizzon Research
Fort Collins, Colorado, Dec. 06, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, The Acute Myeloid Leukemia Market size is expected to grow from USD 1.7 Billion in 2023 to USD 5.1...
Kura Oncology Reports Third Quarter 2023 Financial Results
02 nov. 2023 16h01 HE
|
Kura Oncology, Inc.
– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of...
Kura Oncology to Participate in Three Upcoming Investor Conferences
30 oct. 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix, GlycoMimetics, Arog, Delta-Fly, Jasper, Jazz, Daiichi Sankyo, Amgen, AbbVie, Merck, Eli Lilly
07 août 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix, GlycoMimetics, Arog, Delta-Fly,...
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
07 août 2023 07h00 HE
|
Marker Therapeutics
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
14 juin 2023 07h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
13 juin 2023 16h01 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress
11 juin 2023 03h45 HE
|
Kura Oncology, Inc.
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH...
Kura Oncology to Participate in Stifel Targeted Oncology Days
18 avr. 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
AB Science tiendra une conférence virtuelle sur sa plateforme de déstabilisateurs de microtubules le jeudi 16 mars 2023, de 18h à 19h
15 mars 2023 13h05 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE SUR SA PLATEFORME DE DESTABILISATEURS DE MICROTUBULES LE JEUDI 16 MARS 2023, DE 18h A 19h Paris, 15 mars 2023, 18h AB Science SA...